

# Uterotonic and tocolytic agents

-


© H.S. Helbo-Hansen  
Odense University Hospital  
Denmark



Krusenberg 2014

## Case

- 25-year-old, P0
- Repaired TOF, low risk, moderate PR
- Polyhydramnios
- Vaginal instrumental delivery with EDA
- OT 10 IU/h ~ 17.2 µg/h
- PPH 900 ml, retained products, soft uterus
- Arrives in OR
- HR 120, BP 85/40



# Uterotonic agents

## Oxytocins

- Oxytocin (Syntocinon®)
- Carbetocin (Pabal®)

## Ergot alkaloids

- Methylergometrine (Methergin®)

## Prostaglandins

- Misoprostol (Cytotec®)
- Gemeprost (Cervagem®)
- Carboprost (Prostinfenem®)

# Oxytocin - Severe cardiac complications after

## Maternal death

- Pulmonary hypertension (2 cases)
- Aortic stenosis (2 cases)
- Congestive heart failure (1 case)
- Confidential Enquiries into Maternal Deaths 1997-1999  
JAMA 1967;200:378, Anaesthesia 1998;53:604  
Am J Obstet Gynecol 1970;108:751

## Ventricular tachycardia

- Prolonged QT-syndrome (2 cases)
  - SC Liou. Acta Anaesthesiol Sin 1998;36: 49-52

## Myocardial infarction


- Healthy
  - JP Chilvers. Anaesthesia 2003;58:821-823
- Hypertrophic Obstructive Cardiomyopathy
  - JD Schmitto et al. Acta Anaesthesiol Scand 2008 ;52: 578-9

# Oxytocin-receptors

- uterus




- brain




- breast




- blood vessels



- kidney




- heart




# OT Receptor regulation of vascular tone

Smooth muscle cell




Endothelial cell




H Yazawa et al.  
Br J Pharmacol 1996;117:799

M Thibonnier et al.  
Endocrinology 1999;140:1301


## Effects on systemic circulation




## Effects on pulmonary circulation




## Oxytocin: dose-related decrease in blood pressure




# Oxytocin bolus vs. infusion



## QT interval prolongation after oxytocin




# Myocardial ischaemia following 10 IE oxytocin Spatial ST change vector magnitude (STC-VM)



Svanstrom, M. C. et al. Br. J. Anaesth. 2008 in press


## $ED_{90}$ (95% CI) for oxytocin at cesarean section



JCA Carvalho et al. *Obstet Gynecol* 2004; 104: 1005-10

M Balki et al. *Anesthesiology* 2005; 102 suppl. 1: SOAP A-7

## Oxytocin receptor down-regulation




Oxytocin  
exposure  
during labor

A risk factor  
for PPH

Grotegut et al.  
AOG  
2011;204:56e1-6

# Rat Myometrium pretreated with Oxytocin



# Carbetocin (Pabal®) An Oxytocin Analogue


Oxytocin - Syntocinon ®

T½ 4-5 min.



Carbetocin - Pabal® (oxytocin analog)


T½ 30-50 min.



G Rydén et al. Acta Endocrinol. 1969; 61:425

G Sweeney et al. Curr Ther Research 1990; 47: 528

## Carbetocin vs. Oxytocin Hemodynamics




Minutes after  
start of injection

Carbetocin 100 µg  
Oxytocin 5 IU


over 1 minute

# Methylergometrine (Methergine®)

- Synthetic analogue of ergonovine
- Direct constrictive action on smooth muscle
- No specific ergometrine receptor
- Interaction with:
  - $5\text{-HT}_2$  (serotonergic)
  - $\alpha_1$ -adrenergic,
  - dopaminergic receptors
- Dose response studies?



## Effect on pulmonal and systemic blood pressures




## Cases #9-10

### Occasional severe hypertension

- 37-year-old: pre-eclampsia ➔ 130/100 ➔ ergometrine 0.5 mg ➔ 180/120 ➔ eclamptic fit
- 17-year-old, normotensive ➔ 0.2 mg ergometrine ➔ 190/120 ➔ intracerebral haemorrhage

# Ergometrine

- 28-year-old, CS.
- ergometrine 0.20 mg i.v.
- severe headache
- bilateral amaurosis,
- mild confusion, normal blood pressure
- right hemisensory deficit to all modalities
- arteriography: basilar artery spasm




# RCVS - Reversible Cerebral Vasoconstriction Syndrome

## Postpartum cerebral angiopathy

- Increased risk post partum
- Temporal relationship with methylergometrine
- Elements
  - Segmental cerebral artery vasoconstriction
  - No evidence of aneurysmal SAH
  - Normal/near normal CSF analysis
  - Severe acute headache “thunderclap”
  - With or without neurological signs or symptoms
  - Reversibility within 12 wk

## Case #: ergometrine

- 34-year-old, uterus atonic despite oxytocin
- ergometrine 0.25 mg iv
- ventricular fibrillation
- resuscitated
- intraaortic balloon pump
- spasm of LAD and circumflex
- reversed by intra-coronary nitroglycerin



## Several case reports on ergometrine provoked myocardial infarction

GJ Taylor et al.	Obstet Gynecol	1985; 66: 821
JK Liao et al.	Am J Cardiol	1991; 68: 823
Y Fujiwara et al.	Jpn Heart J	1993; 34: 803
WJ Ko et al.	Int J Cardiol	1998; 63: 81
N Yaegashi et al	Int J Gynecol Obstet	1999; 64: 67
N Sutaria et al.	Heart	2000; 83: 97
HA Mousa et al.	Br J Obstet Gynecol	2000; 107: 939
BCH Tsui et al.	Anesthesiology	2001; 94: 363
Y Hayashi	Intern Med	2003;42:983
YH Lin	Acta Obstet Gynecol Scand	2005:84:1022
A De Labriolle	Cardiovasc Toxicol	
2009;9:46		

# Methylergonovine and risk of Acute Coronary Syndrome and Myocardial Infarction

	Ergonovine n=139,617 (n/100,000)	Not exposed n=2,094,013 (n/100,000)	Risk difference /100,000 (95% CI)
ACS	4.3	2.4	1.81 (-1,69 to 5,32)
AMI	2.9	2.1	0.76 (-2,11 to 3,64)

- Retrospective cohort study
  - USA 2007-2011
  - 2,233,630 deliveries

# Prostaglandins

PGE<sub>1</sub>

PGE<sub>2</sub>

PGF<sub>2α</sub>

Natural

**Alprostadil**  
Prostivas ®

**Dinoprostone**  
Minprostin ®  
Propess ®  
Prostin E2 ®

**Dinoprost**  
Prostin F2alpha ®

Analouges

**Misoprostol**  
Cytotec ®

**Carboprost**  
Prostinfenem ®

**Gemeprost**  
Cervagem ®

**Sulprostone**  
Nalador ®

# Prostaglandins

## Natural


rapid metabolism

half-life  
seconds to minutes


## Analogues

more specific  
first step in metabolism blocked  
active metabolites  
longer half-life  
may differ with regard to cardiovascular effects


# Prostanoid receptors



# Prostanoid receptors




# Prostanoid receptors



# PGE<sub>1</sub>

## Natural PGE<sub>1</sub>


### Alprostadil



ductus dependent heart defects  
cardiomyopathy  
end stage heart failure  
erectile dysfunction

## PGE<sub>1</sub> analogues


### Gemeprost Cervagem®



coronary artery spasm & circulatory collapse

**Largely replaced by misoprostol**


### Misoprostol Cytotec®



negligible circulatory effects

# Misoprostol - Fever

- Case report: Severe hyperthermia (41.9°C)
  - Chong. Obstet Gynecol 1997;90:703,



## Fever:

Usually preceded by shivering


Onset less than 20 min

Peaks at 1-2 hours


Declines over 3 hours

# Misoprostol Pharmacokinetics

Plasma levels (pg/ml)



Termination of pregnancy  
GA 7 - 14 weeks



Vaginal delivery  
GA 37 - 41 weeks


# Misoprostol = Cytotec® (PGE<sub>1</sub> analogue)

- Misoprostol is not more effective and has more side effects than Oxytocin for PPH prophylaxis after vaginal delivery and CS.
  - » Chaudhuri Int J Obstet Gynecol 2012;116:138
  - » Conde-Agudelo et al. AJOG 2013;209:40e1-17
  - » Hua BJOG 2013;120:531
- Oxytocin infusion is more effective than Misoprostol for the treatment of primary PPH.
  - » Mousa et al. Treatment for primary PPH. Cochrane Review 2014
  - » Winikoff et al. Lancet 2010; 375: 210
- Addition of Misoprostol to Oxytocin for treatment of PPH after vaginal delivery confers no benefit.
  - » Widmer et al. Lancet 2010;375:1808
- Addition of Misoprostol to Oxytocin during caesarean section is more effective than oxytocin alone.
  - » Conde-Agudelo et al. AJOG 2013;209:40e1-17

# PGE<sub>2</sub>

## Natural PGE<sub>2</sub>

### Dinoprostone (Minprostin®)



Safe doses/adminstration:


Intracervical 0.5 mg

Vaginal 2-3 mg

Reports on profound hypotension, VT and myocardial infarction with intramyometrial inj. or with larger doses

## PGE<sub>2</sub> analogue

### Sulprostone (Nalador®)



23 case reports, 4 deaths  
severe hypotension  
pulmonary edema  
myocardial infarction  
cardiac arrest


**Withdrawn 1992**

M Winkler. Drug Safety  
1999;20:323

# PGF<sub>2α</sub>

Natural PGF<sub>2α</sub>

Dinoprost




half-life 30 sec.

Withdrawn 2000

PGF<sub>2α</sub> analogue


15-methyl PGF<sub>2α</sub>  
Carboprost  
Prostinfenem®



half-life 30 min.

more potent  
similar pharmaco-dynamic properties

## Bronchoconstriction – 250 µg Carboprost IM



Asthmatic patients may be 8,000 times more sensitive to PGF<sub>2α</sub>

Heslet Andersen. Thorax 1976;31:685 & Mathé BMJ 1973;1:193

# Carboprost - Bronchospasm

- 39-year-old, mild asthma, no medication
- Placental abruption → CS under GA,
- Uterine atony
- Oxytocin and ergometrine
- 250 µg x 2 with a 15 min. interval
  - Severe bronchospasm,
  - Salbutamol, aminophylline
  - ketamine, adrenaline, hydrocortisone
  - Insp. pressure 45-50 cm H<sub>2</sub>O
  - Tidal volume 220 ml
  - PaCO<sub>2</sub> 26 kPa
  - 15 days in ITU



# Carboprost mismatching of ventilation and perfusion


Clinically significant hypoxia  
in 5 of 14 patients

- dose: 1-2 x 250 µg IM
- duration: 10-20 min
- shunt: 11-29%




## Carboprost – Pulmonary edema

- 18-year-old, CS under epidural anaesthesia
- uterine atony despite oxytocin and ergometrine
- 250 µg carboprost intramyometrially
- 5 min later:
  - SpO<sub>2</sub> 89%, dyspnea
  - HR 130-140
  - X-ray: pulmonary edema




## Carboprost - Pulmonary hemodynamics



PPH

Post Partum  
Hemorrhage



# PPH prophylaxis after Cesarean delivery

- Oxytocin bolus dose
  - Elective CS, spinal, no risk factors: 0 – 0.5 IU
  - CS in labor or with risk factors: 3 IU
  - Cardiac disease, pulm. hypertension: 0.1 IU
- Maintenance
  - Oxytocin infusion: 7,5 IU/h for 4 hours
    - (Cardiac disease 2,5 IU/h)
  - Alternatives
    - Carbetocin 100 µg (IV)
    - Misoprostol 400 µg (sublingual or rectal)

L.C. Stephens. Anaesth Intens Care 2012; 40: 247

M. Balki. Anesthesia Clinics 2014; 52: 48-66

A. Conde-Agudelo et al. AJOG 2013; 209: 40.e1-17

D. Leduc et al. J Obstet Gynaecol Can 2009; 31: 980

## Treatment of PPH


- First choice:
  - Oxytocin bolus 5 IE/5 min + infusion 7,5-15 IE/h
    - 40 IE/500 ml NaCl at 125 ml/h ~ 10IU/h
- Supplemented by:
  - Methylergometrine 0.2–0.5 mg IM/IV
  - Carboprost 250 µg IM
    - Buttino L et al. Am J Perinatal 1986;3:241
  - Misoprostol 600 µg oral or sublingual, 1000 µg rectally
    - J Blum et al. Int J Gynecol Obstet 2007;99:S202-S205

## Contraindications

Oxytocin	Hypovolemic shock. Coronary artery disease, fixed CO, aortic stenosis Long QT syndrome Elevated pulmonary artery pressures
Carbetocin	Same as oxytocin + Pre-eclampsia
Methylergotamin	Pre-eclampsia. Hypertension. Coronary artery disease Peripheral vascular disease Elevated pulmonary artery pressures
Misoprostol	?
Carboprost	Asthma. Intracardiac shunting, single ventricle (Fontan circulation) Elevated pulmonary artery pressures.

# Tocolytics

Drugs that  
**inhibit**  
myometrial  
contractions



# Intra-partum Tocolysis

## Indications

- Non-reassuring FHR
- Bying time for neuraxial block
- Prolapsed cord
- Malpresentations
- During CS

## Agents

- |                  |                |
|------------------|----------------|
| • Terbutaline    | cAMP↑          |
| • Nitroglycerine | NO↑            |
| • Atosiban       | OTr antagonist |

## Acute tocolysis during term labour


	Terbutaline 0,25 mg i.v.	Atosiban 6,75 mg i.v.	Nitroglycerine 0,25 mg i.v.
Onset	1-2 min	2 min	1 min
Duration	15 min	8 min	2 min

Ingemarsson et al.  
*Am J Obstet Gynecol*  
1985;153:865


Afschar et al.  
*BJOG*  
2004;111:316

O'Grady et al.  
*J Perinatol*  
2000;1:27-33

# Terbutaline 0.25 mg i.v. Effect on Uterine Activity during Term Labour



# $\beta$ -adrenergic tocolysis for non-reassuring FHR Fenoterol



	Tocolysis (n=193)	Emergency delivery (n=197)	P
BE $\leq$ 12	17.1%	25.4%	0.045
NICU	8.3%	17.8%	0.005

# Nitroglycerin for acute tocolysis

## Positive observational studies and case reports

- Intravenous bolus
  - Emergency situation 250 µg i.v.
- Repeat boluses
  - 50-250 µg at 1-2 min. intervals
- Side-effect
  - Short-lived decrease in blood pressure (up to 40%)

# Nitroglycerin for acute tocolysis

## **Positive RCT**

- Retained placenta
  - 1 mg sublingually
    - Bullarbo et al Int J Obstet Gynecol 2005;91:228

# Nitroglycerin for acute tocolysis

## Negative RCT's

- External version –
  - 800 µg sublingually
    - H Yanny et al. BJOG 2000;107:562
    - E Bujold et al.. Am J Obstet Gynecol 2003;189:1070
- Fetal extraction during CS
  - 500 µg i.v.
    - M David Obstet Gynecol 1998;91:119
- Uterine tone during active labor
  - 3 x 800 µg sublingually
    - CS Buhimschi. Am J Obstet Gynecol 2002;187:235

## Nitroglycerin Acute Tocolysis

- Inconsistent evidence
- The strongest evidence come from clinical reports detailing 346 patients
- Maternal hypotension
- No serious sequelae reported